Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 5/20 | 0.51 |
| ▸ | ACACA | Q13085 | 5/20 | 0.51 |
| ▸ | TACR3 | P29371 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 4/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | MAPK7 | Q13164 | 3/20 | 0.36 |
| ▸ | MGLL | Q99685 | 2/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10170379 | 0.92 | ACACB (0.53) | ACACBACACASCN5ASCN9A | |
| SCHEMBL10170397 | 0.88 | ACACB (0.54) | ACACBACACATACR3MGLL | |
| SCHEMBL550912 | 0.86 | ACACB (0.53) | ACACBACACA | |
| SCHEMBL10170392 | 0.86 | ACACB (0.55) | ACACBACACA | |
| SCHEMBL10170402 | 0.86 | ACACB (0.48) | ACACBACACATACR3ABL1SCN5A | |
| SCHEMBL551729 | 0.85 | ACACB (0.53) | ACACBACACA | |
| SCHEMBL10170343 | 0.85 | ACACB (0.50) | ACACBACACATACR3ABL1SCN5A | |
| SCHEMBL552021 | 0.83 | ACACB (0.50) | ACACBACACA | |
| SCHEMBL551053 | 0.81 | ACACB (0.50) | ACACBACACAMGLL | |
| SCHEMBL10170114 | 0.78 | ACACB (0.46) | ACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110570-B2 | Modulators of acetyl-coenzyme A carboxylase and methods of use thereof | CROPSOLUTION, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-8110570-B2 | Modulators of acetyl-coenzyme A carboxylase and methods of use thereof | CROPSOLUTION, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-20100009982-A1 | Modulators of Acetyl-Coenzyme A Carboxylase and Methods of Use Thereof | CROPSOLUTION, INC. | 2010-01-14 | — | — | US | disclosed |
| US-20100009982-A1 | Modulators of Acetyl-Coenzyme A Carboxylase and Methods of Use Thereof | CROPSOLUTION, INC. | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009982-A1 | Modulators of Acetyl-Coenzyme A Carboxylase and Methods of Use Thereof | ACACA, ACAT1, ACACB | ACACB 3/4885ACACA 1/4885TACR3 2162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.